drugset
drugset / Trial / NCT03697408

Itacitinib + Everolimus in Hodgkin Lymphoma

NCT03697408 ↗

Phase 1/2 Active not recruiting 23 enrolled University of Pennsylvania
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

Timeline

Start
2019-02-11
Primary completion
2024-05-20
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 5 mg —
Subject Itacitinib Small molecule 200 mg —
Subject Itacitinib Small molecule 300 mg —
Subject Itacitinib Small molecule 400 mg —

Indications

classic Hodgkin lymphoma